The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.
 
Nirosha D. Perera
No Relationships to Disclose
 
Jithma P. Abeykoon
No Relationships to Disclose
 
Jorge J. Castillo
Consulting or Advisory Role - Abbvie/Pharmacyclics; Beigene; Janssen; Roche/Genentech
Research Funding - Abbvie (Inst); BeiGene (Inst); Janssen (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
 
Joshua Gustine
No Relationships to Disclose
 
Marzia Varettoni
No Relationships to Disclose
 
Alessandra Tedeschi
No Relationships to Disclose
 
Chiara Cavalloni
No Relationships to Disclose
 
Anna Maria Frustaci
No Relationships to Disclose
 
Matthew J. Maurer
Consulting or Advisory Role - Kite, a Gilead company; MorphoSys; Pfizer
Research Funding - Celgene (Inst); Genentech (Inst); Morphosys (Inst); NanoString Technologies (Inst)
 
Prashant Kapoor
Honoraria - BeiGene; Cellectar; Clinical Care Options; GlaxoSmithKline (Inst); Karyopharm Therapeutics; Pharmacyclics; Sanofi (Inst)
Consulting or Advisory Role - Sanofi (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Sorrento Therapeutics (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Janssen; Sanofi
 
Thomas Matthew Habermann
Consulting or Advisory Role - Celgene; Kite/Gilead
 
Thomas E. Witzig
Consulting or Advisory Role - Abbvie/Genentech (Inst); ADC Therapeutics; Celgene (Inst); Cellectar; Epizyme; Incyte (Inst); Karyopharm Therapeutics; MorphoSys (Inst); Portola Pharmaceuticals; Seagen (Inst); Tessa Therapeutics
Research Funding - Acerta Pharma (Inst); Acrotech Biopharma (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Kura Oncology (Inst)
Patents, Royalties, Other Intellectual Property - I am co-inventor on a patent application filed by Mayo Clinic and pending on the combination of CRM1 inhibitors with salicylates. Please note - simply filed - not even close to being granted. (Inst)
 
Robert A. Kyle
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Pfizer; Pharmacyclics
 
Morie A. Gertz
Honoraria - Abbvie; Akcea Therapeutics; Amgen; Apellis Pharmaceuticals; Celgene; Med Learning Group; Prothena; Research to Practice
Consulting or Advisory Role - Prothena
Travel, Accommodations, Expenses - Celgene; Novartis; Prothena
 
Steven P. Treon
Consulting or Advisory Role - Beigene; Bristol Myers Squibb; Janssen; Pharmacyclics; X4 Pharma
Research Funding - Bristol Myers Squibb (Inst); Janssen; Lilly (Inst); Pharmacyclics; X4 Pharma (Inst)
Patents, Royalties, Other Intellectual Property - my institution holds patents related to use of MYD88 and CXCR4 testing for which a predetermined financial distribution to the laboratory and individuals is provided. I have not received any income to this date related to these patents. (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
Other Relationship - Janssen; Pharmacyclics
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); AI Therapeutics (Inst); Bristol-Myers Squibb (Inst); Regeneron (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Jonas Paludo
Research Funding - Verily (Inst)
Other Relationship - Jazz Pharmaceuticals (Inst)